Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 5/20 | 0.55 |
| ▸ | UBE2M | P61081 | 1/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 6/20 | 0.49 |
| ▸ | CCR3 | P51677 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983168 | 0.86 | CCR8 (0.52) | CCR8FAAHCCR3MGLL | |
| SCHEMBL3599977 | 0.84 | CCR3 (0.57) | CCR8FAAHCCR3MGLL | |
| SCHEMBL2983164 | 0.79 | CCR8 (0.55) | CCR8FAAHCCR3MGLLDRD2 | |
| SCHEMBL3591109 | 0.78 | CCR8 (0.71) | CCR8FAAHCCR3 | |
| SCHEMBL6500525 | 0.78 | CCR8 (0.88) | CCR8CCR3 | |
| SCHEMBL2982171 | 0.77 | HTR2A (0.52) | LTA4HDRD2 | |
| SCHEMBL3599975 | 0.77 | CCR8 (0.58) | CCR8FAAHCCR3 | |
| SCHEMBL27654951 | 0.76 | CHRM4 (0.50) | CCR8FAAH | |
| SCHEMBL2967113 | 0.76 | CHRM4 (0.54) | CCR8 | |
| SCHEMBL2979065 | 0.76 | MMP13 (0.42) | CCR8UBE2MDCUN1D1FAAHCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781590-B2 | Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20070021403-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021403-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | CCR8 2508/4885UBE2M 3836/4885DCUN1D1 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.